Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.

Abstract

BACKGROUND:

Fibrin-rich clot formation in thrombo-occlusive pathologies is currently treated by systemic administration of plasminogen activators (e.g. tPA), to convert fibrin-associated plasminogen to plasmin for fibrinolytic action. However, this conversion is not restricted to clot site only but also occurs on circulating plasminogen, causing systemic fibrinogenolysis and bleeding risks. To address this, past research has explored tPA delivery using clot-targeted nanoparticles.

OBJECTIVES:

We designed a nanomedicine system that can (1) target clots via binding to activated platelets and fibrin, (2) package plasmin instead of tPA as a direct fibrinolytic agent, and (3) release this plasmin triggered by thrombin for clot-localized action.

METHODS:

Clot-targeted thrombin-cleavable nanoparticles (CTNPs) were manufactured using self-assembly of peptide-lipid conjugates. Plasmin loading and its thrombin-triggered release from CTNPs were characterized by UV-visible spectroscopy. CTNP-targeting to clots under flow was studied using microfluidics. Fibrinolytic effect of CTNP-delivered plasmin was studied in vitro using BioFlux imaging and D-dimer analysis and in vivo in a zebrafish thrombosis model.

RESULTS:

Plasmin-loaded CTNPs significantly bound to clots under shear flow and showed thrombin-triggered enhanced release of plasmin. BioFlux studies confirmed that thrombin-triggered plasmin released from CTNPs rendered fibrinolysis similar to free plasmin, further corroborated by D-dimer analysis. In the zebrafish model, CTNP-delivered plasmin accelerated time-to-recanalization, or completely prevented occlusion when infused before thrombus formation.

CONCLUSION:

Considering that the very short circulation half-life (<1 second) of plasmin prevents its systemic use but also makes it safer without off-target drug effects, clot-targeted delivery of plasmin using CTNPs can enable safer and more efficacious fibrinolytic therapy.

• Authors: Michael Sun, M Hao Hao Pontius, Stephanie Yang, Tejal Pendekanti, Shruti Raghunathan, Jordan A Shavit, Anirban Sen Gupta
• Journal: Journal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 21 Issue 4 Pg. 983-994 (04 2023) ISSN: 1538-7836 [Electronic] England
• PMID: 36696210 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.

Chemical References

• Fibrinolysin
• Thrombin
• Fibrin
• Plasminogen
• Tissue Plasminogen Activator

Topics

• Animals
• Fibrinolysin (metabolism)
• Thrombin (chemistry)
• Zebrafish (metabolism)
• Fibrinolysis
• Thrombolytic Therapy
• Thrombosis (drug therapy)
• Fibrin (chemistry)
• Plasminogen
• Nanoparticles
• Tissue Plasminogen Activator